Josh Armenia on Impact of Mutated Gene Analysis in Prostate Cancer

Josh Armenia, PhD
Published: Tuesday, Feb 21, 2017



Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.

This study was a mutational significance analysis, conducted to detect novel genes and pathways in 918 patients with prostate cancer. Twenty-three novel genes were identified as a result.

Due to the large cohort, defining biomarkers in advanced disease are possible, says Armenia.

By comparing the genomic alternation across Gleason scores, markers of risk progression of advanced disease within primary tumors should also be a realistic opportunity.


Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.

This study was a mutational significance analysis, conducted to detect novel genes and pathways in 918 patients with prostate cancer. Twenty-three novel genes were identified as a result.

Due to the large cohort, defining biomarkers in advanced disease are possible, says Armenia.

By comparing the genomic alternation across Gleason scores, markers of risk progression of advanced disease within primary tumors should also be a realistic opportunity.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x